Cogent Biosciences IncChange company Symbol lookupSelect an option...COGT Cogent Biosciences IncLIFW MSP Recovery IncASNS Actelis Networks IncAHI Advanced Health Intelligence LtdOTLK Outlook Therapeutics IncPBHC Pathfinder Bancorp Inc (MARYLAND)CMA Comerica IncIART Integra Lifesciences Holdings CorpARKW.SO ARK Next Generation Internet ETFAGNC Agnc Investment CorpGo
Change company Symbol lookup
Select an option...
COGT Cogent Biosciences Inc
LIFW MSP Recovery Inc
ASNS Actelis Networks Inc
AHI Advanced Health Intelligence Ltd
OTLK Outlook Therapeutics Inc
PBHC Pathfinder Bancorp Inc (MARYLAND)
CMA Comerica Inc
IART Integra Lifesciences Holdings Corp
ARKW.SO ARK Next Generation Internet ETF
AGNC Agnc Investment Corp
Health Care : Biotechnology | Small Cap Blend
Company profileCogent Biosciences, Inc. is a biotechnology company that is focused on developing precision therapies for genetically defined diseases. The Company’s advanced clinical program, bezuclastinib (CGT9486), is a selective tyrosine kinase inhibitor that is designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17 found within the KIT receptor tyrosine kinase, including KIT D816V. KIT D816V is responsible for driving systemic mastocytosis, a serious disease caused by unchecked proliferation of mast cells. In addition to bezuclastinib, the Company is developing a portfolio of novel targeted therapies to help patients fighting serious, genetically driven diseases. The Company has initiated APEX, a Phase II clinical study of bezuclastinib in patients with AdvSM. APEX is an open-label, global, multicenter study evaluating the safety, efficacy, pharmacokinetic, and pharmacodynamic profiles of bezuclastinib.
Postmarket |
|
|
| ||
Market Hours |
|
|
|
|
|
| Latest Earnings Missed Consensus (Q2 ending 06/2023) | Next Earnings Announcement | ||||||
|---|---|---|---|---|---|---|---|
| Q2 Non-GAAP earnings GAAP vs. Non-GAAP EarningsTD Ameritrade displays two types of stock earnings numbers, which are calculated differently and may report different values for the same period. GAAP earnings are the official numbers reported by a company, and non-GAAP earnings are adjusted to be more readable in earnings history and forecasts. Announced August 8, 2023 | -$0.59 | Q2 Consensus of 9 analysts | -$0.55 | Difference from consensus | -8.26% | Q3 Earnings will announce | (Unconfirmed) November 13, 2023 |
Quarterly Earnings History and Estimates
Hide high-low estimates
Draw trendlines
Draw up to 3 lines inside the chart.
COGT's fiscal year ends in December
Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.
Information provided by Copyright © 2023. All rights reserved.
Reuters content is the intellectual property of Reuters. Any copying, republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters is not liable for any errors or delays in content, or for any actions taken in reliance on any content. Reuters, Reuters Logo and the Sphere Logo are trademarks and registered trademarks of the Reuters Group of companies around the world.
Data is provided for information purposes only and is not intended for trading purposes. Reuters shall not be liable for any errors or delay in the content, or for any action taken in reliance on any content. The RIC or Reuters Instrument Code set has been developed and maintained by Reuters and is the intellectual property of Reuters.